Literature DB >> 27537059

Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation.

Sherry S Agabiti1, Yilan Liang1, Andrew J Wiemer1,2.   

Abstract

Geranylgeranyl diphosphate is a 20-carbon isoprenoid phospholipid whose lipid moiety can be post-translationally incorporated into proteins to promote membrane association. The process of geranylgeranylation has been implicated in anti-proliferative effects of clinical agents that inhibit enzymes of the mevalonate pathway (i.e. statins and nitrogenous bisphosphonates) as well as experimental agents that deplete geranylgeranyl diphosphate. Inhibitors of geranylgeranyl diphosphate synthase are an attractive way to block geranylgeranylation because they possess a calcium-chelating substructure to allow localization to bone and take advantage of a unique position of the enzyme within the biosynthetic pathway. Here, we describe recent advances in geranylgeranyl diphosphate synthase expression and inhibitor development with a particular focus on the molecular mechanisms that link geranylgeranyl diphosphate to cell proliferation via geranylgeranylated small GTPases.

Entities:  

Keywords:  Bisphosphonates; GGDPS; Rac; Ras; Rho; small GTPase

Mesh:

Substances:

Year:  2016        PMID: 27537059      PMCID: PMC5532733          DOI: 10.1080/09687688.2016.1213432

Source DB:  PubMed          Journal:  Mol Membr Biol        ISSN: 0968-7688            Impact factor:   2.857


  93 in total

1.  Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.

Authors:  T Scott Reid; Kimberly L Terry; Patrick J Casey; Lorena S Beese
Journal:  J Mol Biol       Date:  2004-10-15       Impact factor: 5.469

Review 2.  Geranylgeranyl diphosphate synthase: an emerging therapeutic target.

Authors:  A J Wiemer; D F Wiemer; R J Hohl
Journal:  Clin Pharmacol Ther       Date:  2011-11-02       Impact factor: 6.875

3.  Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth.

Authors:  Samuel C Falsetti; De-an Wang; Hairuo Peng; Dora Carrico; Adrienne D Cox; Channing J Der; Andrew D Hamilton; Saïd M Sebti
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

4.  A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin.

Authors:  Yifeng Xia; Yi-Liang Liu; Yonghua Xie; Wei Zhu; Francisco Guerra; Shen Shen; Narayana Yeddula; Wolfgang Fischer; William Low; Xiaoying Zhou; Yonghui Zhang; Eric Oldfield; Inder M Verma
Journal:  Sci Transl Med       Date:  2014-11-19       Impact factor: 17.956

5.  Egr-1 enhances drug resistance of breast cancer by modulating MDR1 expression in a GGPPS-independent manner.

Authors:  Weiwei Tao; Jun-Feng Shi; Qian Zhang; Bin Xue; Yu-Jie Sun; Chao-Jun Li
Journal:  Biomed Pharmacother       Date:  2013-02-01       Impact factor: 6.529

6.  Moiety-linkage map reveals selective nonbisphosphonate inhibitors of human geranylgeranyl diphosphate synthase.

Authors:  Shih-Hsun Chen; Sheng-Wei Lin; Shen-Rong Lin; Po-Huang Liang; Jinn-Moon Yang
Journal:  J Chem Inf Model       Date:  2013-08-26       Impact factor: 4.956

7.  Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation.

Authors:  Yonghui Zhang; Rong Cao; Fenglin Yin; Michael P Hudock; Rey-Ting Guo; Kilannin Krysiak; Sujoy Mukherjee; Yi-Gui Gao; Howard Robinson; Yongcheng Song; Joo Hwan No; Kyle Bergan; Annette Leon; Lauren Cass; Amanda Goddard; Ting-Kai Chang; Fu-Yang Lin; Ermond Van Beek; Socrates Papapoulos; Andrew H-J Wang; Tadahiko Kubo; Mitsuo Ochi; Dushyant Mukkamala; Eric Oldfield
Journal:  J Am Chem Soc       Date:  2009-04-15       Impact factor: 15.419

8.  Towards complete sets of farnesylated and geranylgeranylated proteins.

Authors:  Sebastian Maurer-Stroh; Manfred Koranda; Wolfgang Benetka; Georg Schneider; Fernanda L Sirota; Frank Eisenhaber
Journal:  PLoS Comput Biol       Date:  2007-02-23       Impact factor: 4.475

9.  In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells.

Authors:  P Jiang; R Mukthavaram; Y Chao; N Nomura; I S Bharati; V Fogal; S Pastorino; D Teng; X Cong; S C Pingle; S Kapoor; K Shetty; A Aggrawal; S Vali; T Abbasi; S Chien; S Kesari
Journal:  Br J Cancer       Date:  2014-08-05       Impact factor: 7.640

10.  Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.

Authors:  Kaitlyn M Dykstra; Cheryl Allen; Ella J Born; Huaxiang Tong; Sarah A Holstein
Journal:  Oncotarget       Date:  2015-12-08
View more
  9 in total

1.  ω-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors.

Authors:  Nazmul H Bhuiyan; Michelle L Varney; Deep S Bhattacharya; William M Payne; Aaron M Mohs; Sarah A Holstein; David F Wiemer
Journal:  Bioorg Med Chem Lett       Date:  2019-08-20       Impact factor: 2.823

2.  Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor.

Authors:  Staci L Haney; Yashpal S Chhonker; Michelle L Varney; Geoffrey Talmon; Daryl J Murry; Sarah A Holstein
Journal:  Invest New Drugs       Date:  2018-03-02       Impact factor: 3.850

3.  Quantitative determination of a potent geranylgeranyl diphosphate synthase inhibitor using LC-MS/MS: Derivatization and application.

Authors:  Yashpal S Chhonker; Staci L Haney; Robert A Matthiesen; David F Wiemer; Sarah A Holstein; Daryl J Murry
Journal:  J Pharm Biomed Anal       Date:  2018-02-06       Impact factor: 3.935

4.  α-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.

Authors:  Robert A Matthiesen; Michelle L Varney; Pauline C Xu; Alex S Rier; David F Wiemer; Sarah A Holstein
Journal:  Bioorg Med Chem       Date:  2017-10-19       Impact factor: 3.641

5.  Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation.

Authors:  Sherry S Agabiti; Jin Li; Andrew J Wiemer
Journal:  Cell Death Dis       Date:  2017-03-16       Impact factor: 8.469

Review 6.  Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors.

Authors:  Staci L Haney; Veronica S Wills; David F Wiemer; Sarah A Holstein
Journal:  Molecules       Date:  2017-05-27       Impact factor: 4.411

7.  Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment.

Authors:  Gökçen Boran; Sepideh Tavakoli; Ingo Dierking; Ali Reza Kamali; Duygu Ege
Journal:  Sci Rep       Date:  2020-05-08       Impact factor: 4.379

8.  Regulation of the Notch-ATM-abl axis by geranylgeranyl diphosphate synthase inhibition.

Authors:  Sherry S Agabiti; Jin Li; Willie Dong; Michael M Poe; Andrew J Wiemer
Journal:  Cell Death Dis       Date:  2019-09-30       Impact factor: 8.469

Review 9.  Implications on the Therapeutic Potential of Statins via Modulation of Autophagy.

Authors:  Armita Mahdavi Gorabi; Nasim Kiaie; Saeed Aslani; Thozhukat Sathyapalan; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Oxid Med Cell Longev       Date:  2021-07-30       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.